We are not big forecasters here at Abnormal Returns, but we do enjoy these “out of the box” type of annual forecasts from Doug Kass at TheStreet.com.

David Gaffen at MarketBeat has an item on the (largely) ignored Fed meeting.

Mark Maremont and Charles Forelle at the Wall Street Journal introduces us to yet another executive options-related scandal.

Brett Steenbarger at TraderFeed on perceptual distortions in viewing the stock market.

CXO Advisory Group reviews a paper on the “sympathy moves” stocks within an industry show after unexpected earnings.

Mark Hulbert at Barrons.com on the challenges of making (and measuring) the “irrational exuberance” statements.

John Glover and Hamish Risk at Bloomberg.com examine the challenge of exchange-traded credit derivatives will have on Wall Street firms.

What’s $3.15 billion among friends? (via DealBook)

Mark Gongloff at MarketBeat and Douglas A. McIntyre at 24/7 Wall Street on SAC Capital’s bid to derail the big metals merger.

DealBook and FT Alphaville on the long-anticipated Nasdaq takeover bid for the LSE.

Paul Kedrosky at Infectious Greed on the “…largely unremarked IPO resurgence.”

Going Private takes issue with a characterization of a successful LIPO.

Bernard Wysocki Jr. in the Wall Street Journal on the growing influence of “private finance” and their “loan to own” economic model.

FT Alphaville on the trade-off of “permanent capital” for hedge funds.

Ianthe Jeanne Dugan at the Wall Street Journal catches up with NakedShorts on the PlusFunds database story.

Jen Ryan at TheStreet.com on a new investment product to track oil (and presumably other asset) prices.

Sonya Morris at Morningstar.com on the “right” way to index.

Chet Currier at Bloomberg.com on the extended period of underperformance for big company stocks.

Tim Middleton at MSN Money and Yuval Rosenberg at Fortune with fund selections for the new year.

Judy Chevalier in Slate.com on the real issue underlying the debate over pharmaceutical policies.

Thanks for checking in with us here at Abnormal Returns, you can always send us your comments and/or questions.